RESUMO

Resumo Este estudo retrospectivo investigou fatores associados ao tempo para submissão ao primeiro tratamento do câncer de mama entre 12.100 casos assistidos em estabelecimentos de saúde habilitados para a alta complexidade em oncologia no âmbito do SUS localizados no Rio de Janeiro entre 2013 e 2019. Regressão logística multivariada estimou razões de chances e intervalos de 95% de confiança. Foram submetidos ao primeiro tratamento em tempo >60 dias 82,1% dos casos. Entre aqueles sem histórico de diagnóstico anterior, alta escolaridade e estadiamento III e IV exibiram menor probabilidade de submissão ao primeiro tratamento em tempo >60 dias, enquanto tratamento em estabelecimento de saúde não localizado na capital exibiu probabilidade maior. Entre aqueles com histórico de diagnóstico anterior, idade ≥50 anos, raça/cor da pele não branca e estadiamento I exibiram maior probabilidade de submissão ao primeiro tratamento em tempo >60 dias, enquanto alta escolaridade, tratamento em estabelecimento de saúde não localizado na capital e estadiamento IV exibiram probabilidade menor. Em suma, fatores sociodemográficos, clínicos e relacionados ao estabelecimento de saúde estão associados ao tempo para submissão ao primeiro tratamento do câncer de mama.

Abstract The present retrospective study investigated factors associated with time-to-treatment initiation of breast cancer of a cohort of 12,100 cases of health facilities qualified for high complexity in oncology within the scope of the Brazilian Public Health System (SUS) of Rio de Janeiro between 2013 and 2019. Multivariate logistic regression was used to estimate odds ratios and 95% confidence intervals. Of all cases, 82.1% were submitted to the first treatment >60 days. Patients without previous diagnosis history, higher education and in stages III and IV were less likely to have their first treatment >60 days, while treatment at a health facility outside the capital showed a higher probability. Patients with a previous diagnosis history, aged ≥50, non-white race/skin color and in stage I were more likely to be submitted to their first treatment >60 days, while subjects with higher education, treated in a health facility outside the capital and in stage IV showed a lower probability. To summarize, sociodemographic, clinical and health facility-related factors are associated with time-to-treatment initiation of breast cancer.

RESUMO

Introduction: A high prevalence of advanced breast cancer (BC) is a common scenario in Latin America. In Peru, the frequency of BC at Stages III/IV is ≈50% despite implementation of a programme for breast cancer screening (BCS) along the country. We carried out a study to assess the feasibility and develop an instrument to evaluate the knowledge, barriers and perception about BCS in a nationwide pilot study in Peru among candidates for BCS. Methods: We conducted a systematic review of 2,558 reports indexed in PubMed, Scopus, Web of Science, Medline-Ovid and EMBASE, regarding to our study theme. In total, 111 were selected and a 51-items survey was developed (eight items about sociodemographic characteristics). Patients were recruited in public hospitals or private clinics, in rural and urban areas of nine departments of Peru. Results: We surveyed 488 women from: Lima (150), Cajamarca (93), Ica (59), Arequipa (56), Loreto (48), Ancash (38), Junín (15), Puerto Maldonado (15) and Huancavelica (14); 27.9% of them were from rural areas. The mean of age was 53.3 years (standard deviation ± 9.1). Regarding education level, 29.8% had primary, 33.2% secondary and 37.0% higher education. In total, 28.7% of women did not know the term 'mammogram' and 47.1% reported never receiving a BCS (36.9% from urban and 73.5% from rural population). In women that underwent BCS, only 67% knew it is for healthy women. In total, 54.1% of patients had low levels of knowledge about risk factors for BC (i.e. 87.5% of women respond that injuries in the breast produce cancer). Cultural, economic and geographic barriers were significantly associated with having a mammogram where 56.9% of participants considered a cost ≤ 7 USD as appropriate. Mammogram was perceived as too painful for 54.9% of women. In addition, women with a self-perception of low-risk for BC and a fatalistic perception of cancer were less likely to have a BCS. Conclusion: We found that it is feasible to conduct a large-scale study in Peru. The results of this pilot study highlight an urgent need of extensive education and awareness about BCS in Peru.

RESUMO

Abstract Objective To evaluate the underestimation rate in breast surgical biopsy after the diagnosis of radial scar/complex sclerosing lesion through percutaneous biopsy. Data Sources A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. The PubMed, SciELO, Cochrane, and Embase databases were consulted, with searches conducted through November 2020, using specific keywords (radial scar OR complex sclerosing lesion, breast cancer, anatomopathological percutaneous biopsy AND/OR surgical biopsy). Data collection Study selection was conducted by two researchers experienced in preparing systematic reviews. The eight selected articles were fully read, and a comparative analysis was performed. Study selection A total of 584 studies was extracted, 8 of which were selected. One of them included women who had undergone a percutaneous biopsy with a histological diagnosis of radial scar/complex sclerosing lesion and subsequently underwent surgical excision; the results were used to assess the underestimation rate of atypical and malignant lesions. Data synthesis The overall underestimation rate in the 8 studies ranged from 1.3 to 40% and the invasive lesion underestimation rate varied from 0 to 10.5%. Conclusion The histopathological diagnosis of a radial scar/complex sclerosing lesion on the breast is not definitive, and it may underestimate atypical andmalignant lesions, which require a different treatment, making surgical excision an important step in diagnostic evaluation.

Resumo Objetivo Avaliar o grau de discordância entre biópsia percutânea e cirúrgica da mama em pacientes com diagnóstico de cicatriz radiada/lesão esclerosante complexa (CR/LEC) por meio de uma revisão sistemática. Fontes dos dados Foi realizada uma revisão sistemática segundo as recomendações do Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, na sigla em inglês). As bases de dados primárias consultadas foram PubMed, SciELO, Cochrane e Embase, combuscas conduzidas até novembro de 2020, utilizando palavras chaves específicas (cicatriz radiada OU lesão esclerosante complexa, câncer de mama, anatomopatológico de biópsia percutânea E/OU biópsia cirúrgica). Seleção dos estudos A busca dos artigos resultou em um total de 584 estudos, sendo 8 selecionados, os quais incluíam mulheres submetidas a biópsia com diagnóstico histológico de CR/LEC e posteriormente submetidas a exérese cirúrgica para avaliar como desfecho o grau de subestimação de lesões atípicas e malignas. Coleta de dados A seleção dos estudos foi conduzida por dois pesquisadores, com experiência na elaboração de revisão sistemática. Os oito artigos selecionados foram lidos na íntegra e submetidos a uma análise comparativa. Síntese dos dados Cicatrizes radiadas/lesões esclerosante complexas foram associadas com lesões atípicas e malignas após a exérese cirúrgica. O grau de subestimação geral foi calculado pela porcentagem de lesões atípicas e malignas no anatomopatológico após a exérese cirúrgica dentre o total de CR/LEC diagnosticadas, enquanto o grau de subestimação de lesões invasoras foi calculado considerando-se apenas os carcinomas invasivos. O grau de subestimação geral dos estudos selecionados variou de 1,3 a 40%, e o de lesões invasoras de 0 a 10,5%. Conclusão O diagnóstico histopatológico de CR/LEC na mama não é definitivo, podendo subestimar lesões atípicas e malignas, cujo tratamento é distinto, tornando a exérese cirúrgica etapa fundamental na investigação diagnóstica.

Assuntos

RESUMO

ABSTRACT OBJECTIVE: To report the decrease in breast imaging after covid-19 pandemic, obtaining the number of mammograms performed in 2019 and 2020. Additionally, to investigate if there was an increase in the proportion of women undergoing mammography for diagnostic purposes, with palpable lesions. METHOD: This is a cross-sectional study, based on the number of mammograms performed by the Brazilian public health services, provided by DATASUS, an open access database. Mammograms from private institutions were not included. This study compares the number of mammograms performed in 2019 and 2020, in women aged 50-69 years, stratified by month, in each federal state, and the presence of palpable lumps (physician-reported). RESULTS: In total, 1,948,471 mammograms were performed in 2019 and 1,126,688 in 2020, for the population studied. These values represent a 42% decline. Monthly, a significant decreased is observed after April 2020. The results varied slightly according to federal state; yet the entire country was affected. Rondônia was the most affected state, with 67% decline. The proportion of women presenting palpable lumps increased from 7.06% on average in 2019 to 7.94% in 2020 (OR = 1.135, 95%CI 1.125-1.145, p = 0,001). DISCUSSION: The number of mammograms performed in 2020 declined considerably. Out of the women who presented for mammogram, the proportion of palpable lumps was significantly higher in 2020. Considering the detection rate of digital mammography, the loss of 800,000 exams means 4,000 undiagnosed breast cancer cases, by the end of 2020.

Assuntos

RESUMO

SUMMARY OBJECTIVE A previous study has reported that miR-1204 exerted oncogenic effects in breast cancer (BC). The purpose of our paper was to evaluate the expressions of tissue and serum miR-1204 in patients with BC and further investigate its biomarker potential. METHODS The expressions of tissue and serum miR-1204 were investigated by qRT-PCR in 144 BC patients and 38 healthy controls. Chi-square tests were conducted to examine the associations between miR-1204 expressions and clinicopathological factors. Then, the associations of miR-1204s level with the survival of BC patients were determined by performing the Kaplan-Meier and multivariate analysis. The receiver operating characteristics (ROC) and area under the OC curve (AUC) were obtained to validate the diagnostic values of miR-1204. RESULTS We found that the expressions of miR-1204 were increased in both tissue and serum samples from BC patients. Multivariate assays identified tissue and serum miR-1204 overexpression as an independent poor prognostic factor. In addition, ROC curve assays indicated that tissue and serum miR-1204 are potential diagnostic markers of BC. CONCLUSIONS Detection of tissue and serum miR-1204 levels could have clinical potential as a novel prognostic/diagnostic biomarker for BC patients.

RESUMO OBJETIVO Um estudo anterior indicou que o miR-1204 exerce efeitos oncogênicos no Câncer de Mama (CM). O objetivo deste trabalho foi avaliar as expressões de miR-1204 sérico e em tecidos em pacientes com CM e investigar o seu potencial biomarcador. METODOLOGIA As expressões de miR-1204 sérico e em tecidos foram investigadas por qRT-PCR em 144 pacientes com CM e 38 controles saudáveis. Testes qui-quadrados foram realizados para examinar as associações entre as expressões de miR-1204 e os fatores clinicopatológicos. Em seguida, as associações entre nível de miR-1204s e sobrevida de pacientes de CM foram determinadas através de análises de Kaplan-Meier e multivariadas. A Curva Característica de Operação do Receptor (ROC) e área sob a curva (AUC) foram obtidas para validar o valor diagnóstico do MIR-1204. RESULTADOS Descobrimos que as expressões do MIR-1204 estavam aumentadas em amostras de tecido e séricas de pacientes com CM. Análises multivariadas identificaram a superexpressão de miR-1204 sérico e em tecidos como um fator independente de prognóstico ruim. Além disso, as curvas ROC indicaram que o miR-1204 sérico e em tecidos é um possível marcador de diagnóstico de CM. CONCLUSÃO A detecção dos níveis MIR-1204 em tecidos e séricos pode ter potencial clínico como um novo biomarcador de prognóstico/diagnóstico para pacientes de CM.

Assuntos

RESUMO

OBJECTIVE: To demonstrate the frequency of malignancy and histological characteristics of lesions in patients submitted to vacuum-assisted breast biopsy guided by magnetic resonance imaging (MRI). MATERIALS AND METHODS: This was a retrospective study of MRI-guided vacuum-assisted breast biopsies performed between April 2008 and December 2016, in which we analyzed clinical and epidemiological data, as well as the BI-RADS classification and histopathological results. We compared nodules and non-nodular enhancements, in terms of their correlation with malignancy, using chi-square test. RESULTS: Among 215 cases referred for MRI-guided vacuum-assisted breast biopsy, the procedure was contraindicated in 10 cases (5%) and was technically feasible in the remaining 205 (95%). Non-nodular enhancements were observed in 135 cases (66%), and nodules were observed in 70 (34%), with a mean diameter of 2.2 cm (range, 0.5-9.6 cm) and 0.97 cm (range, 0.5-2.2 cm), respectively. Of the 205 lesions analyzed, 43 (21%) were malignant, 129 (63%) were benign, and 33 (16%) were classified as high-risk lesions. The most common histological findings were invasive ductal carcinoma and, in high-risk cases, lobular neoplasia. There was no significant difference between nodules and non-nodular enhancements in terms of the rate of malignancy (p = 0.725). CONCLUSION: In our sample, the overall malignancy rate was 21%. However, to improve the assessment of these results, it is necessary to correlate them with the surgical data and with data from the follow-up of benign cases.

RESUMO

Abstract Objective: To demonstrate the frequency of malignancy and histological characteristics of lesions in patients submitted to vacuum-assisted breast biopsy guided by magnetic resonance imaging (MRI). Materials and Methods: This was a retrospective study of MRI-guided vacuum-assisted breast biopsies performed between April 2008 and December 2016, in which we analyzed clinical and epidemiological data, as well as the BI-RADS classification and histopathological results. We compared nodules and non-nodular enhancements, in terms of their correlation with malignancy, using chi-square test. Results: Among 215 cases referred for MRI-guided vacuum-assisted breast biopsy, the procedure was contraindicated in 10 cases (5%) and was technically feasible in the remaining 205 (95%). Non-nodular enhancements were observed in 135 cases (66%), and nodules were observed in 70 (34%), with a mean diameter of 2.2 cm (range, 0.5-9.6 cm) and 0.97 cm (range, 0.5-2.2 cm), respectively. Of the 205 lesions analyzed, 43 (21%) were malignant, 129 (63%) were benign, and 33 (16%) were classified as high-risk lesions. The most common histological findings were invasive ductal carcinoma and, in high-risk cases, lobular neoplasia. There was no significant difference between nodules and non-nodular enhancements in terms of the rate of malignancy (p = 0.725). Conclusion: In our sample, the overall malignancy rate was 21%. However, to improve the assessment of these results, it is necessary to correlate them with the surgical data and with data from the follow-up of benign cases.

Resumo Objetivo: Demonstrar a frequência de malignidade e as características histológicas das lesões encontradas em pacientes submetidas a biópsia a vácuo guiada por ressonância magnética (RM). Materiais e Métodos: Estudo retrospectivo, realizado no período de abril de 2008 a dezembro de 2016, de biópsia a vácuo guiada por RM, em que se analisaram dados clinicoepidemiológicos, classificação BI-RADS e resultados histopatológicos. A comparação entre os nódulos e os realces não nodulares e a presença de malignidade foi realizada utilizando-se o teste de qui-quadrado. Resultados: Dos 215 casos com indicação de biópsia a vácuo guiada por RM, 10 (5%) foram contraindicados e os restantes 205 (95%) foram tecnicamente viáveis. Foi observado que 66% eram realces não nodulares (135 lesões) e 34% eram nódulos (70 lesões), medindo, em média, 2,2 cm (0,5-9,6 cm) e 0,97 cm (0,5-2,2 cm), respectivamente. Das 205 lesões analisadas, 43 (21%) eram malignas, 129 (63%) eram benignas e 33 (16%) eram de alto risco. O achado histológico mais frequente nos casos de malignidade foi o carcinoma ductal infiltrante, e nos casos de alto risco, as neoplasias lobulares. Não houve diferenças estatisticamente significantes entre os nódulos e realces não nodulares em relação a malignidade (p = 0,725). Conclusão: Na nossa amostra, a taxa global de malignidade foi de 21%. No entanto, é necessário correlação com dados cirúrgicos e seguimento nos casos benignos, para melhor avaliação dos resultados.

RESUMO

INTRODUCCIÓN: El carcinoma papilar sólido de mama es un subtipo poco frecuente de carcinomas mamarios representando el 1 ­ 2 % y principalmente en mujeres postmenopáusicas. Su diagnóstico desde el punto de vista clínico, imagenológico y patológico es difícil. El tratamiento no está estandarizado por el bajo porcentaje de casos reportados, actualmente es aceptada la cirugía conservadora, la radioterapia, existiendo controversia en la hormonoterapia y el vaciamiento axilar, pues las metástasis ganglionares ascienden únicamente al 2 %. Su pronóstico es bueno y la complicación más común es la recidiva local. CASO CLÍNICO: Paciente femenina de 80 años, acudió a consulta por presentar una masa a nivel de mama izquierda al realizarse una autoexploración, donde identificó un nódulo de 2 cm aproximadamente. EVOLUCIÓN: Se realizó una mamografía, ecografía mamaria y la citología mamaria que dio como resultado un tumor, inicialmente se consideró como Phyllodes. Tras el diagnóstico se realizó una lumpectomía, y la patología de la pieza quirúrgica fue de un carcinoma papilar sólido, luego recibió radioterapia y vigilancia médica. CONCLUSIÓN: La autoexploración fue un pilar fundamental en el diagnóstico de este caso y alertó a la paciente a buscar valoración médica. Al tratarse de un caso poco frecuente el diagnóstico definitivo fue la patología.

BACKGROUND: Solid papillary carcinoma of the breast is a rare subtype of mammary carcinomas corresponding to 1 ­ 2 % and mainly in postmenopausal women. It is diagnosis from the clinical, imaging and pathological point of view is difficult. The treatment is not standardized due to the low percentage of cases reported, conservative surgery, radiotherapy is currently accepted, and controversy exists in hormone therapy and axillary emptying, as lymph node metastases amount to only 2 %. It is prognosis is good and the most common complication is local recurrence. CASE REPORT: An 80-year-old female patient attended the consultation by presented a mass at the level of the left breast when performing the self-examination, where identified a 2 cm nodule. EVOLUTION: Mammography, mammary ultrasound and mammary cytology outcome in a tumor, was initially considered as Phyllodes. After the diagnosis a lumpectomy was performed, and the pathology of the surgical piece was of a solid papillary carcinoma, then received radiotherapy and surveillance. CONCLUSIONS: Self-examination was a fundamental pillar in the diagnosis of this case and alerts the patient to seek medical assessment. Being a rare case, the definitive diagnosis was pathology.

Assuntos

RESUMO

OBJECTIVE: To assess the feasibility of contrast-enhanced spectral mammography (CESM) of the breast for assessing the size of residual tumors after neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS: In breast cancer patients who underwent NAC between 2011 and 2013, we evaluated residual tumor measurements obtained with CESM and full-field digital mammography (FFDM). We determined the concordance between the methods, as well as their level of agreement with the pathology. Three radiologists analyzed eight CESM and FFDM measurements separately, considering the size of the residual tumor at its largest diameter and correlating it with that determined in the pathological analysis. Interobserver agreement was also evaluated. RESULTS: The sensitivity, specificity, positive predictive value, and negative predictive value were higher for CESM than for FFDM (83.33%, 100%, 100%, and 66% vs. 50%, 50%, 50%, and 25%, respectively). The CESM measurements showed a strong, consistent correlation with the pathological findings (correlation coefficient = 0.76-0.92; intraclass correlation coefficient = 0.692-0.886). The correlation between the FFDM measurements and the pathological findings was not statistically significant, with questionable consistency (intraclass correlation coefficient = 0.488-0.598). Agreement with the pathological findings was narrower for CESM measurements than for FFDM measurements. Interobserver agreement was higher for CESM than for FFDM (0.94 vs. 0.88). CONCLUSION: CESM is a feasible means of evaluating residual tumor size after NAC, showing a good correlation and good agreement with pathological findings. For CESM measurements, the interobserver agreement was excellent.

OBJETIVO: Avaliar a viabilidade da utilização da mamografia espectral com meio de contraste (CESM) na avaliação do tumor residual em mulheres com câncer de mama submetidas a quimioterapia neoadjuvante. MATERIAIS E MÉTODOS: Foi avaliada a concordância entre a mensuração do tumor residual na CESM e na mamografia digital (FFDM) com os dados histopatológicos de mulheres submetidas a quimioterapia neoadjuvante entre 2011 e 2013. Após as exclusões, três radiologistas analisaram oito CESMs e FFDMs separadamente. A maior dimensão do tumor residual foi considerada para comparação com os resultados histopatológicos. Concordância e correlação da CESM e FFDM com resultados histopatológicos e a concordância interobservador foram avaliadas. RESULTADOS: A CESM teve sensibilidade, especificidade e valores preditivos positivos e negativos maiores que a FFDM - 83,33%, 100%, 100% e 66% versus 50%, 50%, 50% e 25%, respectivamente. A CESM teve correlação boa e consistente com os achados histopatológicos (coeficiente de correlação = 0,76-0,92; coeficiente de correlação intraclasse = 0,692-0,886). A correlação entre FFDM e os achados histopatológicos não foi estatisticamente significante, com consistência questionável (coeficiente de correlação intraclasse = 0,488-0,598). A concordância entre as dimensões do estudo histopatológico foi mais estreita com a CESM do que com a FFDM. A concordância interobservador foi maior na CESM (0,94) do que na FFDM (0,88). CONCLUSÃO: A CESM é viável e pode ser utilizada para avaliação de tumor residual após quimioterapia neoadjuvante. A CESM tem boa correlação e concordância com o estudo histopatológico e excelente concordância interobservador.

RESUMO

Abstract Objective: To assess the feasibility of contrast-enhanced spectral mammography (CESM) of the breast for assessing the size of residual tumors after neoadjuvant chemotherapy (NAC). Materials and methods: In breast cancer patients who underwent NAC between 2011 and 2013, we evaluated residual tumor measurements obtained with CESM and full-field digital mammography (FFDM). We determined the concordance between the methods, as well as their level of agreement with the pathology. Three radiologists analyzed eight CESM and FFDM measurements separately, considering the size of the residual tumor at its largest diameter and correlating it with that determined in the pathological analysis. Interobserver agreement was also evaluated. Results: The sensitivity, specificity, positive predictive value, and negative predictive value were higher for CESM than for FFDM (83.33%, 100%, 100%, and 66% vs. 50%, 50%, 50%, and 25%, respectively). The CESM measurements showed a strong, consistent correlation with the pathological findings (correlation coefficient = 0.76-0.92; intraclass correlation coefficient = 0.692-0.886). The correlation between the FFDM measurements and the pathological findings was not statistically significant, with questionable consistency (intraclass correlation coefficient = 0.488-0.598). Agreement with the pathological findings was narrower for CESM measurements than for FFDM measurements. Interobserver agreement was higher for CESM than for FFDM (0.94 vs. 0.88). Conclusion: CESM is a feasible means of evaluating residual tumor size after NAC, showing a good correlation and good agreement with pathological findings. For CESM measurements, the interobserver agreement was excellent.

Resumo Objetivo: Avaliar a viabilidade da utilização da mamografia espectral com meio de contraste (CESM) na avaliação do tumor residual em mulheres com câncer de mama submetidas a quimioterapia neoadjuvante. Materiais e métodos: Foi avaliada a concordância entre a mensuração do tumor residual na CESM e na mamografia digital (FFDM) com os dados histopatológicos de mulheres submetidas a quimioterapia neoadjuvante entre 2011 e 2013. Após as exclusões, três radiologistas analisaram oito CESMs e FFDMs separadamente. A maior dimensão do tumor residual foi considerada para comparação com os resultados histopatológicos. Concordância e correlação da CESM e FFDM com resultados histopatológicos e a concordância interobservador foram avaliadas. Resultados: A CESM teve sensibilidade, especificidade e valores preditivos positivos e negativos maiores que a FFDM - 83,33%, 100%, 100% e 66% versus 50%, 50%, 50% e 25%, respectivamente. A CESM teve correlação boa e consistente com os achados histopatológicos (coeficiente de correlação = 0,76-0,92; coeficiente de correlação intraclasse = 0,692-0,886). A correlação entre FFDM e os achados histopatológicos não foi estatisticamente significante, com consistência questionável (coeficiente de correlação intraclasse = 0,488-0,598). A concordância entre as dimensões do estudo histopatológico foi mais estreita com a CESM do que com a FFDM. A concordância interobservador foi maior na CESM (0,94) do que na FFDM (0,88). Conclusão: A CESM é viável e pode ser utilizada para avaliação de tumor residual após quimioterapia neoadjuvante. A CESM tem boa correlação e concordância com o estudo histopatológico e excelente concordância interobservador.

RESUMO

ABSTRACT OBJECTIVE To analyze whether the actions of early detection of breast cancer, initiated with the medical request for mammography, differ between users of the Brazilian Unified Health System (SUS) and those who have private health insurance. METHODS From the data collected in the National Health Survey, we estimated the proportions of women who had medical request for mammography according to presence or absence of private health insurance. For assessing the factors related to having mammography medical request, we estimated crude and adjusted odds ratios and respective 95%CI by logistic regression. We also analyzed the main reasons reported for not having performed mammography after medical request, as well as the time between examination and result. RESULTS Of the women interviewed, 66.7% had a medical request for mammography (59.4% among SUS users and 83.9% among those with private health insurance). Having private health insurance, higher education level, and being white were positively associated with having the medical request. Only 5.4% (95%CI 4.8–6.0) of women who received medical request failed to perform mammography – 7.6% were SUS users and 1.7% had health insurance. The most reported reasons for not being able to perform the examination were: not thinking it was necessary; having the test scheduled, but not yet performed; and not being able to schedule it. More than 70% of women received the result with less than one month from its execution. CONCLUSIONS The barriers to access a medical request for mammographic screening for breast cancer are higher among women who depend exclusively on SUS.

RESUMO OBJETIVO Analisar se as ações de detecção precoce para o câncer de mama, iniciadas com o pedido médico de mamografia, diferem entre usuárias do Sistema Único de Saúde (SUS) e aquelas que possuem plano de saúde privado. MÉTODOS A partir dos dados coletados na Pesquisa Nacional de Saúde, foram calculadas as proporções de mulheres que tiveram pedido médico para realização de mamografia segundo ter ou não plano de saúde privado. Para avaliar os fatores relacionados a ter pedido médico de mamografia, foram calculadas odds ratios brutas e ajustadas e os respectivos IC95% por regressão logística. Foram também analisados os principais motivos informados para não ter realizado mamografia após ter o pedido médico, assim como o tempo entre ter realizado o exame e o recebimento do resultado. RESULTADOS Das mulheres entrevistadas, 66,7% tiveram um pedido médico para mamografia (59,4% entre as que eram usuárias do SUS e 83,9% entre as portadoras de plano de saúde privado). Ter plano de saúde privado, maior nível de escolaridade e ser de cor branca se associaram positivamente a ter o pedido médico. Apenas 5,4% (IC95% 4,8–6,0) das mulheres que receberam solicitação médica não conseguiram fazer mamografia – 7,6% eram dependentes do SUS enquanto 1,7% eram portadoras de plano de saúde. Os motivos mais reportados de não conseguir realizar o exame foram: não achar necessário; ter o exame marcado, mas ainda não realizado; e não ter conseguido marcar. Mais de 70% das mulheres receberam o resultado antes de completar um mês da realização. CONCLUSÕES As barreiras de acesso a ter pedido médico para rastreamento mamográfico para o câncer de mama são maiores entre mulheres que dependem exclusivamente do SUS.

Assuntos

RESUMO

Coexistence of breast cancer and tuberculosis is rare. In most cases, involvement by tuberculosis occurs in axillary lymph nodes. We report a case of a 43-years-old patient who had undergone adenomastectomy and left sentinel lymph node biopsy due to a triple negative ductal carcinoma. At the end of adjuvant treatment, the patient had an atypical lymph node in the left axilla. Lymph node was excised, and after laboratory analysis, the diagnosis was ganglion tuberculosis. The patient underwent treatment for primary tuberculosis. The development of these two pathologies can lead to problems in diagnosis and treatment. An accurate diagnosis is important to avoid unnecessary surgical procedures.

A coexistência de câncer de mama e tuberculose é rara. Na maioria das vezes, o acometimento pela tuberculose ocorre nos linfonodos axilares. Relatamos caso clínico de paciente de 43 anos submetida à adenomastectomia e à biópsia de linfonodo sentinela à esquerda devido a um carcinoma ductal triplo negativo. Ao final do tratamento adjuvante, a paciente apresentou linfonodomegalia atípica em axila esquerda. Foi realizado exérese do linfonodo e, após análises laboratoriais, diagnosticou-se tuberculose ganglionar. A paciente foi submetida a tratamento para tuberculose primária. O desenvolvimento dessas duas patologias pode acarretar problemas quanto ao diagnóstico e ao tratamento. O diagnóstico acurado é importante para evitar procedimentos cirúrgicos desnecessários.

Assuntos

RESUMO

OBJECTIVE To assess findings of mammography of and interventions resulting from breast cancer screening in women aged 40-49 years with no increased risk (typical risk) of breast cancer. METHODS This cross-sectional study evaluated women aged 40-49 years who underwent mammography screening in a mastology reference center in Recife, PE, Northeastern Brazil, between January 2010 and October 2011. Women with breast-related complaints, positive findings in the physical examination, or high risk of breast cancer were excluded. RESULTS The 1,000 mammograms performed were classified into the following Breast Imaging-Reporting and Data System (BI-RADS) categories BI-RADS 0, 232; BI-RADS 1, 294; BI-RADS 2, 294; BI-RADS 3, 16; BI-RADS 4A, 2; BI-RADS 5, 1. There was one case of grade II invasive ductal carcinoma and various interventions, including 469 ultrasound scans, 53 referrals to mastologists, 11 cytological examinations, and 8 biopsies. CONCLUSIONS Mammography screening in women aged 40-49 years with typical risk of breast cancer led to the performance of other interventions. However, it also resulted in increased costs without demonstrable efficacy in decreasing mortality. .

OBJETIVO Avaliar os achados mamográficos e as intervenções decorrentes do rastreamento em mulheres de 40 a 49 anos de idade com risco habitual para o câncer de mama. MÉTODOS Estudo transversal com mulheres de 40 a 49 anos, submetidas ao rastreamento mamográfico em centro de referência em mastologia, em Recife, PE, de janeiro de 2010 a outubro de 2011. Foram excluídas mulheres com queixas mamárias, alterações no exame físico e com alto risco para câncer de mama. RESULTADOS Das 1.000 mamografias realizadas, 232 foram BI-RADS 0, 454 BI-RADS 1, 294 BI-RADS 2, 16 BI-RADS 3, duas BI-RADS 4A, uma BI-RADS 4C e uma BI-RADS 5. Observou-se um único caso de carcinoma ductal invasivo grau II e várias intervenções: 469 ultrassonografias, 53 encaminhamentos para a mastologia, 11 citologias e oito biópsias. CONCLUSÕES O rastreamento mamográfico em mulheres de 40 a 49 anos com risco habitual para o câncer de mama leva a outras intervenções e, assim, ao aumento dos custos com eficácia não mostrada para redução da mortalidade. .

Assuntos

RESUMO

OBJETIVO: Analisar o tempo desde o primeiro sintoma até o tratamento de pacientes tratadas para o câncer de mama em hospitais públicos do Distrito Federal, no Brasil Central. MÉTODOS: Trata-se de um estudo transversal analítico. Foram entrevistadas 250 mulheres com diagnóstico de câncer de mama tratadas em 6 hospitais da Secretaria de Estado de Saúde do Distrito Federal (Brasil) no período de novembro de 2009 a janeiro de 2011. Os intervalos de tempo estudados foram o período entre a detecção do sintoma e o tratamento, subdividido nos intervalos até a primeira consulta e após. As outras variáveis analisadas foram: a idade, o estado menopausal, a cor, o nível de escolaridade, a renda familiar média mensal, a procedência, o motivo da primeira consulta, o estadiamento, o tamanho do tumor, a lateralidade, a metástase para linfonodos axilares, a realização de quimioterapia neoadjuvante e o tipo de cirurgia. Para verificar a associação das variáveis com os intervalos de tempo até o tratamento, foi utilizado o teste de Mann-Whitney. RESULTADOS: A média de idade foi de 52 anos, predominando mulheres brancas (57,6%), residentes no Distrito Federal (62,4%), com renda familiar de até dois salários mínimos (78%), que estudaram por até 4 anos (52,4%). O estadiamento da doença em 78,8% das mulheres variou de II a IV. O tempo entre o primeiro sintoma e o tratamento foi de 229 dias (mediana). Após a detecção do primeiro sintoma, 52,9% das mulheres compareceram a uma consulta em até 30 dias e 88,8% tiveram demora de mais de 90 dias para iniciar o tratamento. As mulheres com nível primário de escolaridade apresentaram maior atraso para início do tratamento (p=0,04). CONCLUSÕES: Houve um importante atraso para iniciar o tratamento das mulheres com câncer de mama em hospitais públicos do Distrito Federal sugerindo que esforços devem ser feitos para a redução dos tempos necessários para agendar a consulta médica, diagnosticar e tratar essas pacientes.

PURPOSE: To analyze the time between the first symptom and treatment in patients treated for breast cancer in public hospitals in the Federal District. METHODS: This was a cross-sectional analysis. We interviewed 250 women diagnosed with breast cancer treated in six hospitals of the State Department of Health of the Federal District from November 2009 to January 2011. The time intervals studied were the time between the detection of the symptoms and treatment subdivided into intervals until and after the first medical appointment. The variables were: age, menopausal status, color, educational level, average monthly household income, origin, reason for the initial consultation, staging, tumor size, laterality, metastasis to axillary lymph nodes, neoadjuvant chemotherapy, and type of surgery. The Mann-Whtney test was used to assess the association of these variables with the time intervals until treatment. RESULTS: The mean age was 52 years, with a predominance of white women (57.6%), from the Federal District (62.4%), with a family income of up to 2 minimum wages (78%), and up to four years of schooling (52.4%). The staging of the disease ranged from II to IV in 78.8% of the women. The time between the first symptom and treatment was 229 days (median). After detection of the first symptom, 52.9% of the women attended a consultation within 30 days and 88.8% took more than 90 days to start treatment. Women with elementary school education had a greater delay to the start of treatment (p=0.049). CONCLUSIONS: There was a significant delay to start treatment of women with breast cancer in public hospitals of the Federal District, suggesting that efforts should be made to reduce the time needed to schedule medical appointments and to diagnose and treat these patients.

Assuntos

RESUMO

Objective: To compare the prognosis estimated by standard prognostic criteria versus the prognosis estimated by the Oncotype DX. Methods: A retrospective study was performed on 22 patients with positive estrogen receptor, early-stage breast cancer who had an Oncotype DX recurrence score available. Results: Kappa value between Oncotype DX and standard prognostic criteria was: Adjuvant! (K = 0.091), Adjuvant! (Transbig) (K = 0.182) and National Comprehensive Cancer Network (K = 0.091). The Fisher's exact test did not show correlation between Oncotype and standard prognostic criteria. Conclusion: Standard prognostic criteria showed no correlation with Oncotype DX.

Objetivo: Comparar o prognóstico estimado por critérios prognósticos padronizados e o prognóstico estimado pelo Oncotype DX. Métodos: Foi realizado um estudo retrospectivo envolvendo 22 pacientes com receptor de estrogênio positivo, portadoras de câncer de mama em estágio inicial que possuíam uma pontuação disponível avaliada pelo teste Oncotype DX. Resultados: O valor Kappa entre o teste Oncotype DX e os critérios prognósticos padrão foi: Adjuvant! (K = 0,091), Adjuvant! (Transbig) (K = 0,182) e National Comprehensive Cancer Network (K = 0,091). O teste exato de Fisher não mostrou correlação entre Oncotype DX e os critérios prognósticos padronizados. Conclusão: Os critérios prognósticos padronizados não mostraram correlação com o teste Oncotype DX.

Assuntos

RESUMO

Talvez mais do que qualquer outro câncer, o câncer de mama expõe a paciente não só a um abalo emocional e psicológico, mas também a uma possível modificação da autoestima. A comunicação do câncer de mama ocorre em um momento importante do diagnóstico da enfermidade. Esta revisão tem o objetivo de verificar se existe um padrão de comunicação do diagnóstico de câncer de mama e avaliar os aspectos envolvidos. Foi realizada uma busca nas bases de dados Medline, Lilacs e Biblioteca Cochrane por meio dos descritores “breast neoplasms”, “disclosure”, “persuasive communication”, “diagnosis” e “physician-patient relations”, através da qual foram selecionados oito estudos. Dentre estes, seis abordaram aspectos da comunicação; dois classificam tipos de comunicação; e um analisa as pacientes após o diagnóstico. A conclusão é que não há um padrão único e fixo para a comunicação do diagnóstico do câncer de mama tendo em vista a imensa complexidade e variabilidade de preferências das pacientes.

Perhaps more than any other cancer, breast cancer not only exposes the patient to a psychological and emotional upheaval, but also a possible modification of self-esteem. The communication of breast cancer occurs at an important time of diagnosis of disease. This review aims to establish whether there is a communications standard for the diagnosis of breast cancer and evaluate the issues involved. Was searched in Medline, Lilacs and Cochrane Library using the keywords "breast neoplasms," "disclosure," "persuasive communication", "diagnosis" and "physician-patient relations, through which eight studies were selected . Six of these dealt with aspects of communication, two classified types of communication, and one examines the patients after diagnosis. The conclusion is that there is a single, fixed standard for the communication of the diagnosis of breast cancer in view of the immense complexity and variability of preferences of patients.

Assuntos